Metastatic Colorectal Cancers Withdrawn Phase 2 Trials for Dalotuzumab (DB11840)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01175291FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal CancerTreatment